TY - JOUR
T1 - Optimizing treatment of HER2-positive breast cancer
AU - Gradishar, William J.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - The treatment of HER2-positive breast cancer has benefited from a number of targeted agents. Although adjuvant trastuzumab has dramatically reduced progression-making metastatic disease far less common today-newer treatment advances are also impacting this disease. Dual targeting with pertuzumab and trastuzumab can extend the survival of metastatic disease by more 16 months, but despite such success, resistance to HER2 targeting remains a challenge. Drugs in the pipeline, such as neratinib, may help meet this therapeutic demand. In addition to anti-HER2 agents, chemotherapy is beneficial to patients with tumors 1 cm or larger, but the optimal treatment of smaller tumors is still a work in progress.
AB - The treatment of HER2-positive breast cancer has benefited from a number of targeted agents. Although adjuvant trastuzumab has dramatically reduced progression-making metastatic disease far less common today-newer treatment advances are also impacting this disease. Dual targeting with pertuzumab and trastuzumab can extend the survival of metastatic disease by more 16 months, but despite such success, resistance to HER2 targeting remains a challenge. Drugs in the pipeline, such as neratinib, may help meet this therapeutic demand. In addition to anti-HER2 agents, chemotherapy is beneficial to patients with tumors 1 cm or larger, but the optimal treatment of smaller tumors is still a work in progress.
UR - http://www.scopus.com/inward/record.url?scp=84996565939&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84996565939&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2015.0193
DO - 10.6004/jnccn.2015.0193
M3 - Article
C2 - 25995420
AN - SCOPUS:84996565939
SN - 1540-1405
VL - 13
SP - 649
EP - 651
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
ER -
